Keyphrases
Anti-PD-1 Antibody
10%
Aptamer
28%
Bone Formation
14%
Bone Loss
100%
Bone Metabolic
14%
Bone-targeting
14%
C Domain
100%
Catenin
17%
Cellular Accumulation
10%
Combination Therapy
10%
Dickkopf-1 (DKK1)
100%
Diet-induced
100%
DNA Aptamer
7%
Glucocorticoid Signaling
28%
Glucose Handling
28%
Glucose Uptake
14%
High-fat Diet
100%
Hydroxysteroid Dehydrogenase
100%
Immune Checkpoint Inhibitors
7%
Immune Response
7%
Immunosuppressive Microenvironment
100%
Linker
100%
LRP6
21%
Male Mice
42%
Melanoma B16
10%
Metabolic Disorders
42%
Monotherapy
17%
Myeloid-derived Suppressor Cells
32%
N-domain
100%
Obese Mice
14%
Obesity
100%
Osteoblast
42%
Osteoblastic
100%
Osteogenic Activity
14%
Pharmacologic
10%
Tumor Growth
14%
Tumor Microenvironment
7%
Type I Inhibitor
14%
Pharmacology, Toxicology and Pharmaceutical Science
Aptamer
100%
Catenin
50%
CD8 Antigen
10%
Clinical Trial
10%
Combination Therapy
30%
Disease Free Survival
10%
Immune Checkpoint Inhibitor
20%
Immunosuppressive Agent
100%
Immunotherapy
30%
Low Density Lipoprotein Receptor Related Protein 6
60%
Melanoma B16
30%
Monotherapy
50%
Mouse Model
10%
Multiple Cancer
10%
Neoplasm
10%
Stomach Carcinoma
10%
Triple Negative Breast Cancer
10%
Tumor Growth
60%
Tumor Microenvironment
100%
Biochemistry, Genetics and Molecular Biology
Aptamer
100%
Catenin
50%
CD8
10%
Cell Count
10%
Clinical Trial
10%
Disease Free Survival
10%
DKK1
80%
Downregulation
10%
Gene Mutation
10%
Genetic Approach
10%
Immune Checkpoints
20%
Immune Response
20%
Immunity
10%
LRP6
60%
Molecular Model
10%
Mouse Model
10%
Myeloid
90%
Syngenic
10%
T Cell
20%
Therapeutic Antibodies
10%
Tumor Progression
60%